QuantuMDx's tests will continue to detect all virus strains

Medical Devices

QuantuMDx has confirmed its rapid PCR device, SARS-CoV-2 assays for open PCR platforms and its future respiratory panel (SARS-CoV-2, Flu A, Flu B and RSV A/B), will continue to detect all virus strains, including the Omicron variant.

The alterations in the variant's genome sequences publicly available in GISAID (the online SARS-CoV-2 genome sequence database) did not affect the primer or probe locations, according to in silico research. This is a testament to QuantuMDx's superior assay design, and it further emphasises the company's product quality.

“QuantuMDx's tests will continue to detect all virus strains.“

QuantuMDx's Chief Executive, Jonathan O'Halloran, stated: "Following the detection of this new variant, we have performed a detailed analysis of the mutations to fully assess the reliability of our existing tests and Q-POC. Our assay design strategy, to include three targets, where most only target one or two regions of the SARS-CoV-2 genome, is being proven to be a robust one and with all the new variants continually emerging, we are confident that our tests and device remain able to detect all known variants."

See all the latest jobs in Medical Devices
Return to news